Skip to content
Search

Latest Stories

Excess weight almost doubles risk of womb cancer, researchers from University of Bristol find

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer.

The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent).


This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies.

Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier.

The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

The researchers looked at markers of 14 traits, which could link obesity and womb cancer. They uncovered two hormones -- fasting insulin and testosterone -- which increased the risk of being diagnosed with womb cancer.

By pinpointing exactly how obesity increases the risk of cancer, such as through hormones, scientists in the future could use drugs to reduce or increase the level of these hormones in people already at a higher risk of cancer.

For example, drugs like metformin used in diabetes treatment can reduce the levels of hormones and research suggests this drug also affects cancer risk, though further study is ongoing.

Womb cancer is one of the cancer types most closely linked with obesity. It's the most common gynaecological cancer in high-income countries and is the fourth most common cancer for women in the UK -- one in 36 women will be diagnosed in their lifetime. And of UK womb cancer cases, it's estimated that around a third are caused by being overweight and obese.

Being overweight or obese is the second-highest preventable cause of cancer in the UK. It's estimated that more than one in 20 cancer cases in the UK are caused by excess weight.

Emma Hazelwood, lead author of the paper said, "This study is an interesting first step into how genetic analyses could be used to uncover exactly how obesity causes cancer, and what can be done to tackle it. Links between obesity and womb cancer are well-known but this is one of the largest studies which has looked into exactly why that is on a molecular level. We look forward to furthering research exploring how we can now use this information to help reduce the risk of cancer in people struggling with obesity."

Dr Julie Sharp, head of health information at Cancer Research UK said, "Cancer Research UK has been leading the way in uncovering links between obesity and cancer for years. Studies like this bolster the fact that being overweight or obese is the second biggest cause of cancer in the UK and can help us start to pinpoint why. This will play a pivotal role in uncovering how to prevent and treat cancer in the future."

"More research is needed to investigate exactly which treatments and drugs could be used to manage cancer risk among people struggling with obesity. We already know that being overweight or obese increases your risk of developing 13 different types of cancer. To reduce your cancer risk, it's important to maintain a healthy weight by eating a balanced diet and staying active," Sharp added.

When Kath first started experiencing bleeding in 2013, she put it down to menopause. Despite urges from her daughter to get checked out, she carried on doing the job she loved -- working as a bra fitter in Debenhams Trafford. But just before Christmas in 2013, she had a heavy bleed which prompted her to make an appointment with the doctor.

In January 2014, Kath went to her GP and was referred to Royal Bolton Hospital where she had a biopsy. She was diagnosed with womb cancer.

"When you hear the word cancer your mind runs riot and I was thinking: 'Am I going to live to see my grandchildren grow up?'" Kath said.

"I felt sick as I didn't know what was going on. It was as though I was in a dream. I was devastated when I found out and cried with my husband holding my hand."

Thankfully, Kath's cancer was caught at the earliest possible stage, which meant she could have life-saving surgery which removed her ovaries and cervix. The operation removed all cancer, which meant she didn't need radiotherapy or chemotherapy, and she is now cancer-free.

But her journey did not end there. "After finishing my treatment I wanted to make some changes," Kath said.

"We don't know what caused my cancer, but I have to admit that I was carrying a few extra pounds. So now I exercise and eat better to be healthier. I also wanted to be a role model for my family."

Kath takes part in CRUK's Race For Life every year, raising both money and awareness about cancer.

"Reading some of the words on people's backs about why they were running brought it all back to me about how important this is," Kath said.

"My daughter's notes said: 'Running for our Mum who beat womb cancer!'"

"It's worrying to see that womb cancer rates are on the rise, and although weight isn't the only risk factor, I want to encourage other women to live healthily so that fewer women go through what I went through.

"I hope that my story helps others make a change in their life," Kath concluded.

More For You

Sukhi Basra named NPA vice-chair in historic leadership update with Olivier Picard as new chair

Olivier Picard steps up as NPA chair, Basra as vice-chair

Olivier Picard named new NPA chair

The National Pharmacy Association (NPA) has announced Olivier Picard as the organisation’s new chair.

Picard replaces Nick Kaye whose term comes to an end this week.

Keep ReadingShow less
 RPS honours Professor Tony Avery OBE for excellence in prescribing safety and patient care

Professor Tony Avery OBE

Pic credit: RPS

Professor Tony Avery OBE awarded RPS Honorary Fellowship

The Royal Pharmaceutical Society (RPS) Assembly has awarded an Honorary Fellowship to Professor Tony Avery OBE in recognition of his outstanding contribution to prescribing safety and patient care.

The Honorary Fellowship is given to those who are not eligible for membership of the Society but have either attained a distinction in a particular aspect or aspects of pharmacy, made a distinctive contribution to pharmacy or the RPS, distinguished themselves in any branches of knowledge referred to in the objects of the Society or achieved eminence in public life.

Keep ReadingShow less
US-UK pharmaceutical trade concerns as Liberal Democrat MPs urge protection from Trump tariffs.

UK prime minster Sir Keir Starmer with US president Donald Trump

Pic credit: Getty images

Pharma sector needs protecting from Trump tariffs, warn MPs

A group of Liberal Democrat MPs have written to health secretary Wes Streeting urging him to protect the pharmaceutical industry from US president Donald Trump’s trade war.

The five ministers from Oxfordshire, Olly Glover, Layla Moran, Calum Miller, Charlie Maynard, and Freddie van Mierlo, have warned that Trump’s campaign to raise tariffs has already led to “catastrophic damage”.

Keep ReadingShow less
Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less